Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oneness Biotech Co (LUX:ONEA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Oneness Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was $2,107.20 Mil.
Oneness Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co EV-to-EBIT Related Terms
Oneness Biotech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUX:ONEA vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Oneness Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's EV-to-EBIT falls into.
Oneness Biotech Co's current Enterprise Value is $2,108.30 Mil.
Oneness Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co (LUX:ONEA) has a EV-to-EBIT of 744.98 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oneness Biotech Co and its competitors. According to the industry distribution chart, Oneness Biotech Co ranks #359 out of 373 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Oneness Biotech Co's EV-to-EBIT too high?
Oneness Biotech Co's current EV-to-EBIT is 744.98. The Biotechnology industry median EV-to-EBIT is 15.29. Oneness Biotech Co's value of 744.98 is 4772.3% above this industry median. Based on the distribution chart, Oneness Biotech Co ranks #359 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #359 out of 373 companies for EV-to-EBIT. This places Oneness Biotech Co in the lower half of its industry. The industry median EV-to-EBIT is 15.29. Oneness Biotech Co's value of 744.98 is 4772.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.29, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current EV-to-EBIT of 744.98 is 4772.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oneness Biotech Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current EV-to-EBIT is 744.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current EV-to-EBIT of 744.98. The stock's GF Value™ is $48.97, compared to a current price of $23.60 — trading 51.8% below its estimated fair value. The current EV-to-EBIT is 744.98 and 4772.3% above the Biotechnology industry median of 15.29. Oneness Biotech Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current EV-to-EBIT is 744.98 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 51.8% below its estimated GF Value™ of $48.97.
Key valuation signals for LUX:ONEA:
EV-to-EBIT: 744.98
GF Value™: $48.97 vs. price of $23.60 (51.8% below fair value)
Industry Position: 4772.3% above the Biotechnology median (#359 of 373)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
57GF Score
Get the complete analysis for LUX:ONEA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
